Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by zerboon Sep 30, 2016 3:04pm
185 Views
Post# 25296363

RE:RE:RE:option exercise

RE:RE:RE:option exercise15. SUBSEQUENT EVENTS On September 22, 2016, the Company announces that is has granted incentive stock options under its stock option plan to employees and consultants for the purchase of 1,600,000 common shares of the Company at a price of $0.20 per share. On September 21, 2016, 225,000 options with expiry date on October 21, 2019 were exercised at price of $0.15 per share, 300,000 options with expiry date on June 26, 2025 were exercised at price of $0.16 per share, 450,000 options with expiry date on September 1, 2017 were exercised at price of $0.165 per share and 200,000 options with expiry date on September 21, 2018 were exercised at a price of $0.20 per share. 1,175,000 shares were issued as a result of the exercise. On September 1, 2016, 500,000 options with expiry date on July 15, 2016 were exercised at price of $0.2 per share, and 500,000 options with expiry date on January 16, 2017 were exercised at price of $0.15 per share. 1,000,000 shares were issued as a result of the exercise.
Bullboard Posts